演題詳細

一般口演 / Oral Session

一般口演 100 (Oral Session 100) :節外性B細胞リンパ腫

print

日程
2013年10月13日(日)
時間
15:00 - 16:00
会場
第8会場 / Room No.8 (ロイトン札幌 2F ハイネス)
座長・司会
正木 康史 (Yasufumi Masaki):1
1:金沢医科大学 血液免疫内科学
 
前へ戻る

Retrospective review of 9 patients with intravascular large B-cell lymphoma in the rituximab era

演題番号 : OS-3-149

小西 義延 (Yoshinobu Konishi):1、酒巻 太郎 (Taro Sakamaki):1、三谷 早智子 (Sachiko Mitani):1、辰巳 剛一 (Goichi Tatsumi):1、花岡 知志保 (Chishiho Hanaoka):1、篠原 正信 (Masanobu Shinohara):1、金子 仁臣 (Hitomi Kaneko):1、水谷 知里 (Chisato Mizutani):1、平田 大二 (Hirokazu Hirata):1、通堂 満 (Mitsuru Tsudo):1

1:Osaka Red Cross Hospital, Osaka, Japan

 

Intravascular large B-cell lymphoma (IVLBCL) is a rare disease entity of non-Hodgkin lymphoma, characterized by the selective growth of lymphoma cells within the lumina of vessels. Presenting clinical features of this disease are extremely variable and nonspecific, which results in the delay of timely and accurate diagnosis and fatal complications.We retrospectively evaluated the clinical features and outcome of nine patients diagnosed as IVLBCL from January 2006 to March 2013 in our institution. The median age was 69 years (range 40 - 77 years). The male: female ratio was 4: 5. 6 patients presented with B symptoms and 5 patients were considered to have central nervous system (CNS) involvement. The median time to definitive diagnosis from the development of symptoms was 68 days (range 23 - 443 days). All patients received anthracycline-based chemotherapy with rituximab and 6 patients received intrathecal therapy. After a median follow-up time among all patients of 37 months (range 4 - 59 months), overall survival (OS) at 3 years were 76.2%. 6 patients experienced a relapse and the median time to next treatment (TTNT) among those was 7 months (range 2 - 17 months). Patients diagnosed within 50 days since the development of symptoms showed a tendency to improved clinical outcomes.In conclusion, anthracycline-based chemotherapy with rituximab can be recommended as first-line therapy, although it has room of improvement. Also, because timely and accurate diagnosis can improve clinical outcomes, it is quite important to obtain better knowledge about this rare type of lymphoma.

前へ戻る